Aurealis Therapeutics is a pioneering brand with a mission to develop curative therapies for chronic wounds, cancer, and inflammatory diseases. Their innovative 4-in-1 platform combines cell and gene therapy to provide multi-target treatments. With a focus on creating solid clinical safety and efficacy data, Aurealis aims to address the needs of patients with conditions such as Diabetic Foot Ulcer and other chronic wounds, as well as deadly cancers.

Led by a dedicated management team, including CEO Juha Yrjänheikki, COO Laurent Décory, and CMO Haritha Samaranayake, Aurealis Therapeutics is dedicated to revolutionizing the field of regenerative medicine. They have a team of experts, including scientists, genetic engineers, and clinical project managers, who work diligently to bring their vision to life.

Aurealis Therapeutics seeks to engage with strategic partners to ensure that their groundbreaking technology platform benefits millions of patients worldwide. With a strong commitment to improving patient outcomes, this brand is making significant strides in the field of regenerative medicine.